CHILDHOOD CANCER REPOSITORY

Powered by

Alex's Lemonade Stand Foundation

Neuroblastoma

RequestCell LinePhase of Therapy1 StageMYCN*DiseaseAge
(months)
p53DT5
(hours)
CHLA-90PD-BMT4NNeuroblastoma 102NF59
CHLA-136PD-BMT4ANeuroblastoma 36F44
NB-1643Dx4ANeuroblastoma <36  
NB-EBc1PD4NNeuroblastoma <36  

1 - Phase of therapy for the patient at the time the specimen used to derive the cell line was obtained
Dx (Diagnosis): cell lines derived from samples of patients prior to treatment
PD (Progressive Disease): cell lines derived from samples of patients who relapsed after chemotherapy
PD-BMT: cell lines derived from samples of patients who relapsed after chemotherapy and bone marrow transplantation
PD-PM: cell lines derived from samples of post-mortem patients who relapsed after chemotherapy

2 -MYCN oncogene amplification
N: MYCN Non-Amplified
A: MYCN Amplified

3 - TP53 gene function
F: Functional
N: Non-Functional

4 - EWS/FLI1 Status
FLI1: friend leukemia insertion - chromosome 11, t(11;22)
ERG: ets-related gene - chromosome 21, t(21;22)

ALK mutation

WT: Wild Type

TMM:Telomere Maintenance mechanism

✓ = Available/available upon request

SQ- subcutaneous injection

TV- intravenous (tail vein)

EST- ever shorter telomeres, i.e. telomerase and ALT negative

TERTTERT+- telomerase positive

ALT - alternate lengthening of telomeres, C-circle positive

DT - Doubling Time (hours)